<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Featherston AL</submitter><funding>Takeda Pharmaceuticals International Co.</funding><funding>National Institute of General Medical Sciences</funding><funding>NIGMS NIH HHS</funding><pagination>702-707</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC7961808</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>371(6530)</volume><pubmed_abstract>We report the catalytic stereocontrolled synthesis of dinucleotides. We have demonstrated, for the first time to our knowledge, that chiral phosphoric acid (CPA) catalysts control the formation of stereogenic phosphorous centers during phosphoramidite transfer. Unprecedented levels of diastereodivergence have also been demonstrated, enabling access to either phosphite diastereomer. Two different CPA scaffolds have proven to be essential for achieving stereodivergence: peptide-embedded phosphothreonine-derived CPAs, which reinforce and amplify the inherent substrate preference, and C2-symmetric BINOL-derived CPAs, which completely overturn this stereochemical preference. The presently reported catalytic method does not require stoichiometric activators or chiral auxiliaries and enables asym</pubmed_abstract><journal>Science (New York, N.Y.)</journal><pubmed_title>Catalytic asymmetric and stereodivergent oligonucleotide synthesis.</pubmed_title><pmcid>PMC7961808</pmcid><funding_grant_id>R35 GM132092</funding_grant_id><pubmed_authors>Engl OD</pubmed_authors><pubmed_authors>Featherston AL</pubmed_authors><pubmed_authors>Kwon Y</pubmed_authors><pubmed_authors>Pompeo MM</pubmed_authors><pubmed_authors>Leahy DK</pubmed_authors><pubmed_authors>Miller SJ</pubmed_authors></additional><is_claimable>false</is_claimable><name>Catalytic asymmetric and stereodivergent oligonucleotide synthesis.</name><description>We report the catalytic stereocontrolled synthesis of dinucleotides. We have demonstrated, for the first time to our knowledge, that chiral phosphoric acid (CPA) catalysts control the formation of stereogenic phosphorous centers during phosphoramidite transfer. Unprecedented levels of diastereodivergence have also been demonstrated, enabling access to either phosphite diastereomer. Two different CPA scaffolds have proven to be essential for achieving stereodivergence: peptide-embedded phosphothreonine-derived CPAs, which reinforce and amplify the inherent substrate preference, and C2-symmetric BINOL-derived CPAs, which completely overturn this stereochemical preference. The presently reported catalytic method does not require stoichiometric activators or chiral auxiliaries and enables asym</description><dates><release>2021-01-01T00:00:00Z</release><publication>2021 Feb</publication><modification>2025-04-04T19:54:01.122Z</modification><creation>2025-04-04T19:54:01.122Z</creation></dates><accession>S-EPMC7961808</accession><cross_references><pubmed>33574208</pubmed><doi>10.1126/science.abf4359</doi></cross_references></HashMap>